Scinopharm Taiwan (TPE:1789) Cyclically Adjusted FCF per Share: NT$0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1789 Scinopharm Taiwan Ltd TPE:1789
81 GF Score
Price NT$19.95
GF Value NT$27.41
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Cyclically Adjusted FCF per Share?

Scinopharm Taiwan TPE:1789 +0.50% 81 Cyclically Adjusted FCF per Share is NT$0.00 as of Mar. 2026. GuruFocus rates TPE:1789 with a GF Score™ of 81/100 and a GF Value™ of NT$27.41 (Modestly Undervalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Scinopharm Taiwan's adjusted free cash flow per share for the three months ended in Mar. 2026 was NT$0.147. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$0.00 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Scinopharm Taiwan was 12.00% per year. The lowest was 7.20% per year. And the median was 7.20% per year.

As of today (2026-07-21), Scinopharm Taiwan's current stock price is NT$19.95. Scinopharm Taiwan's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was NT$0.00. Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Scinopharm Taiwan was 57.57. The lowest was 18.06. And the median was 34.93.


Scinopharm Taiwan  (TPE:1789) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Scinopharm Taiwan was 57.57. The lowest was 18.06. And the median was 34.93.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Scinopharm Taiwan Cyclically Adjusted FCF per Share Related Terms


Scinopharm Taiwan Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Cyclically Adjusted FCF per Share Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.73 0.80 0.90 0.90

Scinopharm Taiwan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.89 0.90 0.90 0.00

TPE:1789 vs ZTS, UTHR: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Cyclically Adjusted Price-to-FCF falls into.


TPE:1789
81GF Score
Scinopharm Taiwan Ltd TPE:1789
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Scinopharm Taiwan's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.147/330.2130*330.2130
=0.147

Current CPI (Mar. 2026) = 330.2130.

Scinopharm Taiwan Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.069 241.018 0.095
201609 0.316 241.428 0.432
201612 0.634 241.432 0.867
201703 0.127 243.801 0.172
201706 -0.094 244.955 -0.127
201709 0.486 246.819 0.650
201712 0.202 246.524 0.271
201803 0.324 249.554 0.429
201806 0.057 251.989 0.075
201809 0.579 252.439 0.757
201812 0.409 251.233 0.538
201903 0.489 254.202 0.635
201906 0.009 256.143 0.012
201909 0.214 256.759 0.275
201912 0.148 256.974 0.190
202003 0.291 258.115 0.372
202006 0.069 257.797 0.088
202009 0.270 260.280 0.343
202012 0.341 260.474 0.432
202103 0.038 264.877 0.047
202106 0.011 271.696 0.013
202109 0.069 274.310 0.083
202112 0.111 278.802 0.131
202203 0.073 287.504 0.084
202206 0.228 296.311 0.254
202209 0.340 296.808 0.378
202212 0.030 296.797 0.033
202303 0.165 301.836 0.181
202306 -0.273 305.109 -0.295
202309 0.073 307.789 0.078
202312 -0.022 306.746 -0.024
202403 0.376 312.332 0.398
202406 -0.008 314.175 -0.008
202409 -0.033 315.301 -0.035
202412 0.260 315.605 0.272
202503 0.091 319.799 0.094
202506 -0.014 322.561 -0.014
202509 -0.029 324.800 -0.029
202512 0.330 324.054 0.336
202603 0.147 330.213 0.147

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$0.00 mean?
Scinopharm Taiwan (TPE:1789) has a Cyclically Adjusted FCF per Share of NT$0.00 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Cyclically Adjusted FCF per Share too high?
Scinopharm Taiwan's current Cyclically Adjusted FCF per Share is NT$0.00. Overall, Scinopharm Taiwan has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Scinopharm Taiwan's Cyclically Adjusted FCF per Share of NT$0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Cyclically Adjusted FCF per Share is NT$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.41, compared to a current price of NT$19.95 — trading 27.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$0.00. Scinopharm Taiwan's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Cyclically Adjusted FCF per Share is NT$0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$19.95 is trading 27.2% below its estimated GF Value™ of NT$27.41. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Cyclically Adjusted FCF per Share: NT$0.00
  • GF Value™: NT$27.41 vs. price of NT$19.95 (27.2% below fair value)
  • GF Score™: 81/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
81GF Score

Get the complete analysis for TPE:1789

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$19.95
Price
NT$27.41
GF Value